Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pleural Neoplasms | 31 | 2024 | 609 | 7.010 |
Why?
|
Mesothelioma | 30 | 2024 | 807 | 6.310 |
Why?
|
Lung Neoplasms | 43 | 2024 | 13262 | 2.440 |
Why?
|
Neoplasm Staging | 24 | 2024 | 11152 | 1.380 |
Why?
|
Solitary Pulmonary Nodule | 6 | 2020 | 270 | 1.310 |
Why?
|
Mediastinal Neoplasms | 4 | 2022 | 402 | 1.250 |
Why?
|
Pneumonectomy | 13 | 2021 | 1111 | 1.200 |
Why?
|
Pleural Diseases | 3 | 2015 | 137 | 1.160 |
Why?
|
Thoracic Surgery, Video-Assisted | 2 | 2020 | 277 | 0.980 |
Why?
|
Lung Diseases, Interstitial | 7 | 2024 | 911 | 0.750 |
Why?
|
Tomography, X-Ray Computed | 30 | 2024 | 20509 | 0.730 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 9 | 2023 | 5251 | 0.710 |
Why?
|
Diagnostic Imaging | 7 | 2019 | 3527 | 0.690 |
Why?
|
Diffusion Magnetic Resonance Imaging | 5 | 2024 | 2782 | 0.680 |
Why?
|
Multiple Pulmonary Nodules | 3 | 2020 | 167 | 0.670 |
Why?
|
Bronchoscopy | 3 | 2022 | 911 | 0.610 |
Why?
|
Anesthesia, General | 3 | 2022 | 1166 | 0.590 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2016 | 471 | 0.490 |
Why?
|
Benchmarking | 1 | 2021 | 1044 | 0.470 |
Why?
|
Arthritis, Rheumatoid | 7 | 2024 | 3763 | 0.470 |
Why?
|
Bronchial Fistula | 1 | 2013 | 83 | 0.440 |
Why?
|
Thoracic Neoplasms | 3 | 2019 | 266 | 0.400 |
Why?
|
Radiology | 5 | 2024 | 2102 | 0.390 |
Why?
|
Magnetic Resonance Imaging | 10 | 2021 | 36290 | 0.350 |
Why?
|
Unnecessary Procedures | 1 | 2013 | 413 | 0.350 |
Why?
|
Surgery, Computer-Assisted | 2 | 2015 | 1008 | 0.330 |
Why?
|
Tumor Burden | 6 | 2020 | 1895 | 0.330 |
Why?
|
Bronchiectasis | 2 | 2022 | 139 | 0.300 |
Why?
|
Aged | 45 | 2024 | 169152 | 0.300 |
Why?
|
Humans | 96 | 2024 | 760621 | 0.300 |
Why?
|
Anesthesia | 1 | 2018 | 1584 | 0.290 |
Why?
|
Myxoma | 1 | 2008 | 114 | 0.290 |
Why?
|
Aged, 80 and over | 22 | 2024 | 58995 | 0.290 |
Why?
|
Middle Aged | 51 | 2024 | 220352 | 0.280 |
Why?
|
Primary Prevention | 1 | 2013 | 1207 | 0.260 |
Why?
|
Airway Obstruction | 2 | 2022 | 662 | 0.250 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 3202 | 0.240 |
Why?
|
Heart Neoplasms | 1 | 2008 | 360 | 0.230 |
Why?
|
Male | 54 | 2024 | 359744 | 0.230 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7475 | 0.230 |
Why?
|
Sensitivity and Specificity | 10 | 2024 | 14660 | 0.230 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2019 | 296 | 0.220 |
Why?
|
Pulmonary Artery | 4 | 2014 | 1921 | 0.220 |
Why?
|
Clinical Trials as Topic | 2 | 2019 | 8056 | 0.220 |
Why?
|
Female | 56 | 2024 | 391270 | 0.220 |
Why?
|
Positron-Emission Tomography | 8 | 2022 | 6465 | 0.210 |
Why?
|
Lung Transplantation | 2 | 2012 | 1305 | 0.210 |
Why?
|
Internship and Residency | 1 | 2023 | 5870 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2018 | 4024 | 0.210 |
Why?
|
Contrast Media | 8 | 2024 | 5305 | 0.200 |
Why?
|
Prognosis | 11 | 2024 | 29658 | 0.200 |
Why?
|
Pneumothorax | 2 | 2020 | 379 | 0.200 |
Why?
|
Hyperthermia, Induced | 2 | 2018 | 417 | 0.200 |
Why?
|
CA-125 Antigen | 1 | 2024 | 279 | 0.190 |
Why?
|
Public Opinion | 2 | 2022 | 481 | 0.190 |
Why?
|
Lung | 8 | 2022 | 9994 | 0.180 |
Why?
|
Angiography | 3 | 2011 | 1605 | 0.180 |
Why?
|
Adult | 34 | 2024 | 219994 | 0.180 |
Why?
|
Pulmonary Embolism | 5 | 2014 | 2543 | 0.180 |
Why?
|
Intraoperative Care | 2 | 2015 | 768 | 0.180 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2943 | 0.180 |
Why?
|
Atrial Appendage | 1 | 2024 | 292 | 0.170 |
Why?
|
Neoplasm Invasiveness | 4 | 2020 | 3618 | 0.170 |
Why?
|
Emphysema | 1 | 2022 | 240 | 0.170 |
Why?
|
Postoperative Complications | 2 | 2015 | 15697 | 0.170 |
Why?
|
Retrospective Studies | 22 | 2022 | 80372 | 0.170 |
Why?
|
Cisplatin | 2 | 2018 | 1644 | 0.170 |
Why?
|
Iohexol | 2 | 2012 | 204 | 0.170 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2012 | 3340 | 0.150 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2020 | 326 | 0.150 |
Why?
|
Predictive Value of Tests | 5 | 2024 | 15289 | 0.150 |
Why?
|
Motion | 2 | 2020 | 779 | 0.150 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9276 | 0.150 |
Why?
|
Reproducibility of Results | 11 | 2024 | 20080 | 0.150 |
Why?
|
Mass Screening | 1 | 2013 | 5423 | 0.150 |
Why?
|
Dermatitis | 1 | 2019 | 200 | 0.150 |
Why?
|
Survival Rate | 7 | 2024 | 12808 | 0.150 |
Why?
|
Education, Distance | 1 | 2021 | 258 | 0.150 |
Why?
|
Students, Medical | 2 | 2021 | 1927 | 0.140 |
Why?
|
Reference Standards | 1 | 2021 | 1004 | 0.140 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 629 | 0.140 |
Why?
|
Prospective Studies | 8 | 2024 | 54303 | 0.140 |
Why?
|
Pulmonary Emphysema | 4 | 2016 | 688 | 0.140 |
Why?
|
Expert Testimony | 1 | 2019 | 361 | 0.140 |
Why?
|
Idiopathic Pulmonary Fibrosis | 1 | 2022 | 502 | 0.140 |
Why?
|
Follow-Up Studies | 6 | 2023 | 39261 | 0.130 |
Why?
|
Biopsy | 2 | 2022 | 6771 | 0.130 |
Why?
|
Respiration | 2 | 2020 | 1654 | 0.120 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2020 | 741 | 0.120 |
Why?
|
Diagnosis, Differential | 5 | 2024 | 12965 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 421 | 0.120 |
Why?
|
Neoplasms | 2 | 2021 | 22072 | 0.120 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 895 | 0.120 |
Why?
|
Positive-Pressure Respiration | 1 | 2018 | 636 | 0.120 |
Why?
|
Clinical Clerkship | 1 | 2020 | 563 | 0.120 |
Why?
|
Cardiac Tamponade | 1 | 2005 | 174 | 0.110 |
Why?
|
Deoxycytidine | 1 | 2018 | 873 | 0.110 |
Why?
|
Perfusion Imaging | 1 | 2015 | 196 | 0.110 |
Why?
|
Ductus Arteriosus, Patent | 1 | 2005 | 218 | 0.110 |
Why?
|
Combined Modality Therapy | 5 | 2018 | 8552 | 0.110 |
Why?
|
Pleurisy | 1 | 2013 | 54 | 0.110 |
Why?
|
Algorithms | 3 | 2021 | 13981 | 0.100 |
Why?
|
Consensus | 2 | 2019 | 3113 | 0.100 |
Why?
|
Bronchi | 1 | 2016 | 848 | 0.100 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 2017 | 707 | 0.100 |
Why?
|
Lung Volume Measurements | 1 | 2013 | 376 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2018 | 2506 | 0.100 |
Why?
|
Radiotherapy | 1 | 2019 | 1504 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2015 | 2821 | 0.100 |
Why?
|
Carcinoma in Situ | 1 | 2017 | 796 | 0.100 |
Why?
|
Pandemics | 2 | 2023 | 8624 | 0.100 |
Why?
|
Artifacts | 1 | 2020 | 1898 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2019 | 6315 | 0.090 |
Why?
|
Image Enhancement | 3 | 2012 | 2881 | 0.090 |
Why?
|
Mycobacterium | 1 | 2012 | 250 | 0.090 |
Why?
|
Radiography, Thoracic | 3 | 2020 | 1296 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1728 | 0.090 |
Why?
|
Young Adult | 8 | 2024 | 58741 | 0.090 |
Why?
|
Registries | 3 | 2018 | 8469 | 0.090 |
Why?
|
Logistic Models | 4 | 2022 | 13314 | 0.090 |
Why?
|
Bronchopulmonary Sequestration | 1 | 2010 | 43 | 0.090 |
Why?
|
Radiography, Interventional | 2 | 2015 | 1114 | 0.090 |
Why?
|
Radionuclide Imaging | 1 | 2013 | 1975 | 0.080 |
Why?
|
Incidental Findings | 1 | 2014 | 698 | 0.080 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 3 | 2016 | 3224 | 0.080 |
Why?
|
Asbestos | 1 | 2011 | 251 | 0.080 |
Why?
|
Body Burden | 1 | 2009 | 158 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2053 | 0.080 |
Why?
|
Gadolinium DTPA | 1 | 2012 | 823 | 0.080 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12531 | 0.080 |
Why?
|
Radiation Dosage | 2 | 2014 | 1958 | 0.080 |
Why?
|
Iodine | 1 | 2010 | 286 | 0.080 |
Why?
|
Receptor, erbB-2 | 1 | 2018 | 2554 | 0.070 |
Why?
|
Pleural Effusion, Malignant | 1 | 2009 | 103 | 0.070 |
Why?
|
Tracheal Diseases | 1 | 2008 | 115 | 0.070 |
Why?
|
Mesentery | 1 | 2008 | 202 | 0.070 |
Why?
|
Pulmonary Valve Stenosis | 1 | 2008 | 172 | 0.070 |
Why?
|
Bronchial Diseases | 1 | 2008 | 151 | 0.070 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2009 | 301 | 0.070 |
Why?
|
Immune Tolerance | 1 | 2016 | 2299 | 0.070 |
Why?
|
Fibromatosis, Aggressive | 1 | 2008 | 125 | 0.070 |
Why?
|
Heart Defects, Congenital | 1 | 2024 | 4673 | 0.070 |
Why?
|
Palliative Care | 3 | 2021 | 3607 | 0.070 |
Why?
|
Cohort Studies | 6 | 2021 | 41335 | 0.070 |
Why?
|
Phlebography | 1 | 2008 | 325 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2018 | 13630 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2019 | 15840 | 0.070 |
Why?
|
Immunohistochemistry | 2 | 2018 | 11071 | 0.070 |
Why?
|
Aneurysm, False | 1 | 2008 | 257 | 0.070 |
Why?
|
Flow Cytometry | 1 | 2016 | 5870 | 0.060 |
Why?
|
Radiography | 2 | 2013 | 6965 | 0.060 |
Why?
|
Radiographic Image Enhancement | 1 | 2010 | 875 | 0.060 |
Why?
|
Proteoglycans | 1 | 2009 | 801 | 0.060 |
Why?
|
Treatment Outcome | 8 | 2021 | 65017 | 0.060 |
Why?
|
Radiation Protection | 1 | 2009 | 425 | 0.060 |
Why?
|
Feasibility Studies | 1 | 2016 | 5201 | 0.060 |
Why?
|
Dyspnea | 1 | 2013 | 1352 | 0.060 |
Why?
|
Thoracic Surgical Procedures | 1 | 2009 | 348 | 0.060 |
Why?
|
Risk Factors | 9 | 2022 | 74359 | 0.060 |
Why?
|
Smoking | 2 | 2024 | 9073 | 0.060 |
Why?
|
Pulmonary Medicine | 1 | 2007 | 221 | 0.060 |
Why?
|
Respiratory Tract Infections | 1 | 2012 | 1007 | 0.060 |
Why?
|
Breast Diseases | 1 | 2007 | 443 | 0.060 |
Why?
|
Biopsy, Needle | 1 | 2009 | 1630 | 0.060 |
Why?
|
Electronic Health Records | 1 | 2021 | 4775 | 0.060 |
Why?
|
Software | 1 | 2017 | 4419 | 0.050 |
Why?
|
Reoperation | 1 | 2013 | 4291 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3844 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2009 | 2381 | 0.050 |
Why?
|
Pelvis | 1 | 2008 | 743 | 0.050 |
Why?
|
Survival Analysis | 2 | 2016 | 10182 | 0.050 |
Why?
|
Surgical Wound Infection | 1 | 2012 | 1527 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2014 | 3486 | 0.050 |
Why?
|
Lung Diseases | 1 | 2013 | 1915 | 0.050 |
Why?
|
Genomics | 1 | 2018 | 5794 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 468 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
Decision Support Systems, Clinical | 1 | 2011 | 1164 | 0.050 |
Why?
|
United States | 4 | 2019 | 72461 | 0.050 |
Why?
|
Regression Analysis | 1 | 2012 | 6360 | 0.050 |
Why?
|
Ethanol | 1 | 2008 | 1323 | 0.050 |
Why?
|
Mucin-5B | 1 | 2022 | 147 | 0.050 |
Why?
|
Sarcoidosis | 1 | 2007 | 520 | 0.050 |
Why?
|
Peritoneal Neoplasms | 1 | 2008 | 707 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2283 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1215 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11712 | 0.050 |
Why?
|
Thrombosis | 1 | 2005 | 3052 | 0.050 |
Why?
|
Gene Expression | 1 | 2014 | 7588 | 0.050 |
Why?
|
Observer Variation | 3 | 2014 | 2601 | 0.040 |
Why?
|
Risk Assessment | 3 | 2012 | 24123 | 0.040 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2009 | 2007 | 0.040 |
Why?
|
Emergency Medical Services | 1 | 2011 | 1925 | 0.040 |
Why?
|
Biopsy, Fine-Needle | 2 | 2016 | 1110 | 0.040 |
Why?
|
Case-Control Studies | 4 | 2022 | 22053 | 0.040 |
Why?
|
Vital Capacity | 2 | 2016 | 965 | 0.040 |
Why?
|
Lower Extremity | 1 | 2008 | 1194 | 0.040 |
Why?
|
Life Style | 2 | 2022 | 3896 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 2008 | 1152 | 0.040 |
Why?
|
X-Rays | 1 | 2020 | 307 | 0.040 |
Why?
|
Radiopharmaceuticals | 1 | 2009 | 2634 | 0.040 |
Why?
|
Gadolinium | 1 | 2024 | 959 | 0.040 |
Why?
|
Foundations | 1 | 2019 | 97 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2016 | 10181 | 0.040 |
Why?
|
Indocyanine Green | 1 | 2020 | 236 | 0.040 |
Why?
|
Adolescent | 5 | 2024 | 87810 | 0.040 |
Why?
|
International Agencies | 1 | 2019 | 244 | 0.040 |
Why?
|
Disease Progression | 3 | 2022 | 13502 | 0.040 |
Why?
|
Venous Thrombosis | 1 | 2008 | 1299 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2020 | 6828 | 0.040 |
Why?
|
Coloring Agents | 1 | 2020 | 562 | 0.040 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9411 | 0.040 |
Why?
|
Artificial Intelligence | 2 | 2024 | 2557 | 0.040 |
Why?
|
Telomere | 1 | 2024 | 933 | 0.040 |
Why?
|
Forced Expiratory Volume | 2 | 2016 | 1809 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2009 | 1895 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2020 | 6544 | 0.040 |
Why?
|
Curriculum | 2 | 2021 | 3718 | 0.040 |
Why?
|
Bronchial Arteries | 1 | 2016 | 21 | 0.040 |
Why?
|
Demography | 1 | 2022 | 1650 | 0.040 |
Why?
|
Total Lung Capacity | 1 | 2016 | 149 | 0.030 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2019 | 454 | 0.030 |
Why?
|
Adrenal Gland Neoplasms | 1 | 2021 | 733 | 0.030 |
Why?
|
Graft vs Host Disease | 1 | 2008 | 3025 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2008 | 2758 | 0.030 |
Why?
|
Databases, Factual | 2 | 2024 | 8035 | 0.030 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2011 | 8950 | 0.030 |
Why?
|
Remission Induction | 1 | 2019 | 2392 | 0.030 |
Why?
|
Pain | 1 | 2008 | 5066 | 0.030 |
Why?
|
Autoantibodies | 1 | 2022 | 2118 | 0.030 |
Why?
|
Mediastinum | 1 | 2014 | 266 | 0.030 |
Why?
|
Methotrexate | 1 | 2019 | 1719 | 0.030 |
Why?
|
Mycobacterium avium Complex | 1 | 2012 | 59 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 1636 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4899 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2022 | 5785 | 0.020 |
Why?
|
Boston | 2 | 2015 | 9280 | 0.020 |
Why?
|
Precancerous Conditions | 1 | 2017 | 977 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2005 | 1832 | 0.020 |
Why?
|
Time Factors | 3 | 2020 | 40165 | 0.020 |
Why?
|
Odds Ratio | 1 | 2022 | 9716 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2021 | 4902 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 2 | 2009 | 17790 | 0.020 |
Why?
|
Glucocorticoids | 1 | 2019 | 2145 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5649 | 0.020 |
Why?
|
Antirheumatic Agents | 1 | 2019 | 1374 | 0.020 |
Why?
|
Prevalence | 3 | 2012 | 15687 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2015 | 1791 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2019 | 2802 | 0.020 |
Why?
|
Computer Graphics | 1 | 2011 | 341 | 0.020 |
Why?
|
Fibromatosis, Abdominal | 1 | 2008 | 21 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3568 | 0.020 |
Why?
|
Proteomics | 1 | 2022 | 3817 | 0.020 |
Why?
|
Treatment Failure | 1 | 2015 | 2648 | 0.020 |
Why?
|
Diaphragm | 1 | 2010 | 351 | 0.020 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2532 | 0.020 |
Why?
|
Lod Score | 1 | 2009 | 602 | 0.020 |
Why?
|
Comorbidity | 2 | 2016 | 10551 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3465 | 0.020 |
Why?
|
Respiratory Function Tests | 1 | 2013 | 1683 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2015 | 2897 | 0.020 |
Why?
|
Immunotherapy | 1 | 2023 | 4642 | 0.020 |
Why?
|
Incidence | 2 | 2019 | 21392 | 0.020 |
Why?
|
Vinblastine | 1 | 2008 | 487 | 0.020 |
Why?
|
Massachusetts | 2 | 2011 | 8803 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4573 | 0.020 |
Why?
|
Syndrome | 1 | 2013 | 3280 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2015 | 3529 | 0.020 |
Why?
|
Spirometry | 1 | 2009 | 924 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2014 | 3775 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2021 | 4319 | 0.020 |
Why?
|
User-Computer Interface | 1 | 2011 | 1403 | 0.010 |
Why?
|
Siblings | 1 | 2007 | 824 | 0.010 |
Why?
|
Kinetics | 1 | 2011 | 6377 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 2008 | 857 | 0.010 |
Why?
|
Doxorubicin | 1 | 2008 | 2209 | 0.010 |
Why?
|
Pedigree | 1 | 2009 | 4578 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2014 | 12159 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3531 | 0.010 |
Why?
|
Phenotype | 2 | 2009 | 16546 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2007 | 21025 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2021 | 8986 | 0.010 |
Why?
|
Computer Simulation | 1 | 2012 | 6218 | 0.010 |
Why?
|
Pain Measurement | 1 | 2008 | 3528 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2007 | 2640 | 0.010 |
Why?
|
Models, Biological | 1 | 2012 | 9467 | 0.010 |
Why?
|
Animals | 2 | 2015 | 167963 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2009 | 15789 | 0.010 |
Why?
|
Mice | 1 | 2009 | 81208 | 0.000 |
Why?
|